Journal
GENE THERAPY
Volume 13, Issue 1, Pages 60-66Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3302599
Keywords
sodium iodide symporter; MUC1; radioiodine; ovarian cancer
Categories
Funding
- NATIONAL CANCER INSTITUTE [P50CA091956] Funding Source: NIH RePORTER
- NCI NIH HHS [CA91956] Funding Source: Medline
Ask authors/readers for more resources
Ovarian cancer represents the fifth leading cause of cancer death among women in the United States, with 416 000 deaths expected this year. This study was carried out to investigate the potential of sodium iodide symporter (NIS)-mediated radioiodide therapy as a novel approach for ovarian cancer treatment. Radioiodide is routinely and effectively used for the treatment of benign and malignant thyroid disease as a result of native thyroidal expression of NIS, which mediates iodide uptake. In vitro gene transfer studies in ovarian cancer cells revealed a 12- and five-fold increase in iodide uptake when transduced with Ad/CMV/NIS or Ad/MUC1/NIS, respectively. Western blot/immunohistochemistry confirmed NIS protein expression. In vivo ovarian tumor xenografts were infected with the adenoviral constructs. I-123 imaging revealed a clear image of the CMV/NIS-transduced tumor, with a less intense image apparent following infection with MUC1/NIS. Therapeutic doses of I-131 following CMV/NIS infection caused a mean 53% reduction in tumor volume (P<0.0001). MUC1/NIS-transduced tumors did not regress, although at 8 weeks following therapy, tumor volume was significantly less that of control animals (166 versus 332%, respectively, P<0.05). This study represents a promising first step investigating the potential for NIS-mediated radioiodide imaging and therapy of ovarian tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available